Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Executive Vice President | December 11, 2012 | December 13, 2012 |
| AbbVie Inc.ABBV · Entity 2800 | Vice Chairman | February 25, 2022 | March 01, 2022 |
| CrowdStrike Holdings, Inc.CRWD · Entity 1172 | Director | September 18, 2026 | September 22, 2026 |
| GENERAL DYNAMICS CORPGD · Entity 2916 | Director | September 16, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date December 11, 2012 · Filed December 13, 2012
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 179,338 |
Ending reported balance
After 2012-12-11 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2012-12-11 · Exercise / conversion · Acquired 36,985 · Balance 216,323 Row 2 · 2012-12-11 · Exercise / conversion · Acquired 67,200 · Balance 283,523 Row 3 · 2012-12-11 · Exercise / conversion · Acquired 1,045 · Balance 284,568 Row 4 · 2012-12-11 · Exercise / conversion · Acquired 2,395 · Balance 286,963 Row 5 · 2012-12-11 · Exercise / conversion · Acquired 652 · Balance 287,615 Row 6 · 2012-12-11 · Exercise / conversion · Acquired 11,500 · Balance 299,115 Row 7 · 2012-12-11 · Sale · Disposed 119,777 · Balance 179,338 |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.34 · Expires 2015-02-17 | Direct | 0 |
Reported balance
After 2012-12-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2012-12-11 · Exercise / conversion · Disposed 36,985 · Balance 0 F1: Employee stock option granted pursuant to Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.54 · Expires 2017-02-15 | Direct | 0 |
Reported balance
After 2012-12-11 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2012-12-11 · Exercise / conversion · Disposed 67,200 · Balance 0 F1: Employee stock option granted pursuant to Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.16 · Expires 2013-02-13 | Direct | 0 |
Reported balance
After 2012-12-11 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2012-12-11 · Exercise / conversion · Disposed 1,045 · Balance 0 F2: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.74 · Expires 2014-02-19 | Direct | 0 |
Reported balance
After 2012-12-11 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2012-12-11 · Exercise / conversion · Disposed 2,395 · Balance 0 F2: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.01 · Expires 2013-02-13 | Direct | 0 |
Reported balance
After 2012-12-11 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2012-12-11 · Exercise / conversion · Disposed 652 · Balance 0 F2: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.60 · Expires 2021-02-17 | Direct | 38,333 |
Reported balance
After 2012-12-11 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2012-12-11 · Exercise / conversion · Disposed 11,500 · Balance 38,333 F3: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
Filing footnotes · ownership attribution and instrument terms
F1: Employee stock option granted pursuant to Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3.
F2: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3.
F3: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
AbbVie Inc.
Report date February 25, 2022 · Filed March 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 248,002 |
Reported balance
After 2022-02-25 transaction · row 1
1 source rowRow 1 · 2022-02-25 · Tax withholding · Disposed 40,490 · Balance 248,002 |
CrowdStrike Holdings, Inc.
Report date September 18, 2026 · Filed September 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A common stockSEC Table I · non-derivative | Direct | 38,724 |
Reported balance
After 2026-09-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-18 · Grant · Acquired 68 · Balance 38,724 F1: The shares represent fully vested RSUs issued in lieu of quarterly cash retainer(s) payable under the issuer's Outsider Director Compensation Policy. The RSUs immediately converted into shares of the issuer's Class A Common Stock. F2: On July 2, 2026, the Issuer executed a four-for-one stock split with a record date of June 25, 2026, effected in the form of a one-time special stock dividend on each share of the company's Class A common stock. F3: Includes shares to be issued in connection with the vesting of one or more RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares represent fully vested RSUs issued in lieu of quarterly cash retainer(s) payable under the issuer's Outsider Director Compensation Policy. The RSUs immediately converted into shares of the issuer's Class A Common Stock.
F2: On July 2, 2026, the Issuer executed a four-for-one stock split with a record date of June 25, 2026, effected in the form of a one-time special stock dividend on each share of the company's Class A common stock.
F3: Includes shares to be issued in connection with the vesting of one or more RSUs.
GENERAL DYNAMICS CORP
Report date September 16, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,792 |
Reported balance
After 2026-09-16 transaction · row 1
1 source rowRow 1 · 2026-09-16 · Grant · Acquired 105 · Balance 13,792 F1: Reflects stock received in lieu of director fees in accordance with outside directors' compensation program. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects stock received in lieu of director fees in accordance with outside directors' compensation program.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2020 Filed Mar 3, 2020 19:30 UTC | GENERAL DYNAMICS CORP GD · Entity 2916 | Tax withholdingCommon Stock | 86 | $161.42 | $13,882.12 |
DisclosureSEC source: 0001209191-20-014983 · doc4.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,101 F1 · kind: Represents the withholding of shares of Common Stock under the General Dynamics Corporation equity compensation plan to satisfy tax withholding obligations in connection with the release of restricted shares. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:56 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 33,745 | $85.42 | $2,882,497.90 |
DisclosureSEC source: 0001179110-20-002863 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,901 Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 23:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 114,566 | $0.00 Strike: $93.50 | $0.00 |
DisclosureSEC source: 0001179110-20-002130 · edgar.xml · derivative · entry 5 Schumacher Laura J · CIK 0001319245 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,566 Underlying: Common Stock · 114,566 shares Expires 2030-02-19 F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 38,189 on February 20, 2021, 38,189 on February 20, 2022, and 38,188 on February 20, 2023. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 23:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 11,136 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002130 · edgar.xml · nonDerivative · entry 4 Schumacher Laura J · CIK 0001319245 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,646 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 23:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 8,479 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002130 · edgar.xml · nonDerivative · entry 3 Schumacher Laura J · CIK 0001319245 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,510 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 23:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 14,989 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002130 · edgar.xml · nonDerivative · entry 2 Schumacher Laura J · CIK 0001319245 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,031 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 23:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 41,562 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002130 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,042 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 20:45 UTC | GENERAL DYNAMICS CORP GD · Entity 2916 | Tax withholdingCommon Stock | 115 | $177.98 | $20,467.70 |
DisclosureSEC source: 0001209191-20-001691 · doc4.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,187 F1 · kind: Represents the withholding of shares of Common Stock under the General Dynamics Corporation equity compensation plan to satisfy tax withholding obligations in connection with the release of restricted shares. Read SEC document |
| December 17, 2019 Filed Dec 19, 2019 20:36 UTC | GENERAL DYNAMICS CORP GD · Entity 2916 | GrantCommon Stock | 118 | $179.87 | $21,224.66 |
DisclosureSEC source: 0001209191-19-061286 · doc4.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,302 F1 · kind: Reflects stock received in lieu of director fees in accordance with outside directors' compensation program. Read SEC document |
| November 04, 2019 Filed Nov 8, 2019 22:14 UTC | AbbVie Inc. ABBV · Entity 2800 | GiftCommon Stock, $0.01 par value | 358 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-011579 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,480 Read SEC document |
| September 17, 2019 Filed Sep 18, 2019 19:58 UTC | GENERAL DYNAMICS CORP GD · Entity 2916 | GrantCommon Stock | 111 | $190.01 | $21,091.11 |
DisclosureSEC source: 0001209191-19-050028 · doc4.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,184 F1 · kind: Reflects stock received in lieu of director fees in accordance with outside directors' compensation program. Read SEC document |
| September 16, 2019 Filed Sep 18, 2019 20:25 UTC | AbbVie Inc. ABBV · Entity 2800 | PurchaseCommon stock, $0.01 par value | 25,000 | $70.42 | $1,760,522.50 |
DisclosureSEC source: 0001179110-19-010451 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,838 F1 · price: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $69.86 to $70.73, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 18, 2019 Filed Jun 19, 2019 20:05 UTC | GENERAL DYNAMICS CORP GD · Entity 2916 | GrantCommon Stock | 123 | $171.40 | $21,082.20 |
DisclosureSEC source: 0001209191-19-037986 · doc4.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,073 F1 · kind: Reflects stock received in lieu of director fees in accordance with outside directors' compensation program. Read SEC document |
| March 18, 2019 Filed Mar 19, 2019 21:17 UTC | GENERAL DYNAMICS CORP GD · Entity 2916 | GrantCommon Stock | 125 | $169.80 | $21,225.00 |
DisclosureSEC source: 0001209191-19-020374 · doc4.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,950 F1 · kind: Reflects stock received in lieu of director fees in accordance with outside directors' compensation program. Read SEC document |
| March 14, 2019 Filed Mar 15, 2019 21:53 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 25,000 | $80.00 | $2,000,000.00 |
DisclosureSEC source: 0001179110-19-003945 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,838 Read SEC document |
| March 06, 2019 Filed Mar 7, 2019 22:00 UTC | GENERAL DYNAMICS CORP GD · Entity 2916 | GrantStock Options · Derivative | 2,590 | $0.00 Strike: $167.61 | $0.00 |
DisclosureSEC source: 0001209191-19-017816 · doc4.xml · derivative · entry 2 Schumacher Laura J · CIK 0001319245 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,590 Underlying: Common Stock · 2,590 shares Expires 2029-03-05 F2 · derivative.exercise_date: Fifty percent become exercisable on 03/06/2021 and the remaining fifty percent become exercisable on 03/06/2022. Read SEC document |
| March 06, 2019 Filed Mar 7, 2019 22:00 UTC | GENERAL DYNAMICS CORP GD · Entity 2916 | GrantCommon Stock | 445 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-017816 · doc4.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,825 F1 · shares: Represents shares of restricted stock subject to service-based vesting that will be released three years after the grant date. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 21:58 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 24,275 | $79.41 | $1,927,677.75 |
DisclosureSEC source: 0001179110-19-003091 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,838 Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:21 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (Right to buy) · Derivative | 68,535 | $0.00 Strike: $79.02 | $0.00 |
DisclosureSEC source: 0001179110-19-002372 · edgar.xml · derivative · entry 5 Schumacher Laura J · CIK 0001319245 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,535 Underlying: Common Stock · 68,535 shares Expires 2029-02-20 F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 22,845 on February 21, 2020, 22,845 on February 21, 2021, and 22,845 on February 21, 2022. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:21 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 8,481 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002372 · edgar.xml · nonDerivative · entry 4 Schumacher Laura J · CIK 0001319245 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,113 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:21 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 14,989 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002372 · edgar.xml · nonDerivative · entry 3 Schumacher Laura J · CIK 0001319245 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,632 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:21 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 13,110 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002372 · edgar.xml · nonDerivative · entry 2 Schumacher Laura J · CIK 0001319245 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,643 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:21 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 18,211 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002372 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,533 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 17:34 UTC | GENERAL DYNAMICS CORP GD · Entity 2916 | Tax withholdingCommon Stock | 115 | $155.64 | $17,898.60 |
DisclosureSEC source: 0001209191-19-001725 · doc4.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,380 F1 · kind: Represents the withholding of shares of Common Stock under the General Dynamics Corporation equity compensation plan to satisfy tax withholding obligations in connection with the release of restricted shares. Read SEC document |
| December 28, 2018 Filed Jan 2, 2019 21:49 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 25,000 | $90.00 | $2,250,000.00 |
DisclosureSEC source: 0001179110-19-000048 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,322 Read SEC document |
| December 24, 2018 Filed Dec 28, 2018 17:01 UTC | AbbVie Inc. ABBV · Entity 2800 | GiftCommon stock, $0.01 par value | 119 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-014289 · edgar.xml · nonDerivative · entry 2 Schumacher Laura J · CIK 0001319245 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,322 Read SEC document |
| December 21, 2018 Filed Dec 28, 2018 17:01 UTC | AbbVie Inc. ABBV · Entity 2800 | GiftCommon stock, $0.01 par value | 1,495 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-014289 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,441 Read SEC document |
| December 18, 2018 Filed Dec 19, 2018 21:36 UTC | GENERAL DYNAMICS CORP GD · Entity 2916 | GrantCommon Stock | 128 | $165.65 | $21,203.20 |
DisclosureSEC source: 0001209191-18-063486 · doc4.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,495 F1 · kind: Reflects stock received in lieu of director fees in accordance with outside directors' compensation program. Read SEC document |
| December 13, 2018 Filed Dec 14, 2018 22:13 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 49,852 | $88.60 | $4,416,887.20 |
DisclosureSEC source: 0001179110-18-013894 · edgar.xml · nonDerivative · entry 2 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,936 Read SEC document |
| December 13, 2018 Filed Dec 14, 2018 22:13 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 112,530 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-013894 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,788 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2, above, upon certification by the Compensation Committee of AbbVie's Board of Directors of the achievement of specified strategic milestones. Read SEC document |
| December 04, 2018 Filed Dec 7, 2018 22:15 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to buy) · Derivative | 94,140 | $0.00 Strike: $51.42 | $0.00 |
DisclosureSEC source: 0001179110-18-013566 · edgar.xml · derivative · entry 6 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 94,140 shares Expires 2024-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 04, 2018 Filed Dec 7, 2018 22:15 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 9,300 | $91.77 | $853,502.85 |
DisclosureSEC source: 0001179110-18-013566 · edgar.xml · nonDerivative · entry 5 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,258 F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.515 to $92.97, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 04, 2018 Filed Dec 7, 2018 22:15 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 10,000 | $92.37 | $923,705.00 |
DisclosureSEC source: 0001179110-18-013566 · edgar.xml · nonDerivative · entry 4 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,558 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.98 to $92.97, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 04, 2018 Filed Dec 7, 2018 22:15 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 41,642 | $93.66 | $3,900,385.44 |
DisclosureSEC source: 0001179110-18-013566 · edgar.xml · nonDerivative · entry 3 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,558 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.00 to $93.97, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 04, 2018 Filed Dec 7, 2018 22:15 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 33,198 | $94.34 | $3,131,959.08 |
DisclosureSEC source: 0001179110-18-013566 · edgar.xml · nonDerivative · entry 2 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,200 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.98 to $94.98, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 04, 2018 Filed Dec 7, 2018 22:15 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 94,140 | $51.42 | $4,840,678.80 |
DisclosureSEC source: 0001179110-18-013566 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,398 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 27, 2018 Filed Nov 30, 2018 22:13 UTC | AbbVie Inc. ABBV · Entity 2800 | GiftCommon Stock, $0.01 par value | 59 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-013331 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,258 Read SEC document |
| September 18, 2018 Filed Sep 20, 2018 18:31 UTC | GENERAL DYNAMICS CORP GD · Entity 2916 | GrantCommon Stock | 105 | $201.60 | $21,168.00 |
DisclosureSEC source: 0001209191-18-051763 · doc4.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,367 F1 · kind: Reflects stock received in lieu of director fees in accordance with outside directors' compensation program. Read SEC document |
| June 18, 2018 Filed Jun 19, 2018 19:40 UTC | GENERAL DYNAMICS CORP GD · Entity 2916 | GrantCommon Stock | 109 | $194.61 | $21,212.49 |
DisclosureSEC source: 0001209191-18-038500 · doc4.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,262 F1 · kind: Reflects stock received in lieu of director fees in accordance with outside directors' compensation program. Read SEC document |
| March 16, 2018 Filed Mar 19, 2018 19:01 UTC | GENERAL DYNAMICS CORP GD · Entity 2916 | GrantCommon Stock | 95 | $222.56 | $21,143.20 |
DisclosureSEC source: 0001209191-18-020531 · doc4.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,153 F1 · kind: Reflects stock received in lieu of director fees in accordance with outside directors' compensation program. Read SEC document |
| March 07, 2018 Filed Mar 8, 2018 21:34 UTC | GENERAL DYNAMICS CORP GD · Entity 2916 | GrantStock Options · Derivative | 1,990 | $0.00 Strike: $223.93 | $0.00 |
DisclosureSEC source: 0001209191-18-018039 · doc4.xml · derivative · entry 2 Schumacher Laura J · CIK 0001319245 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,990 Underlying: Common Stock · 1,990 shares Expires 2028-03-06 F2 · derivative.exercise_date: Fifty percent become exercisable on 03/07/2020 and the remaining fifty percent become exercisable on 03/07/2021. Read SEC document |
| March 07, 2018 Filed Mar 8, 2018 21:34 UTC | GENERAL DYNAMICS CORP GD · Entity 2916 | GrantCommon Stock | 335 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-018039 · doc4.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,058 F1 · shares: Represents shares of restricted stock subject to service-based vesting that will be released three years after the grant date. Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 22:28 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 25,000 | $117.85 | $2,946,147.50 |
DisclosureSEC source: 0001179110-18-003331 · edgar.xml · nonDerivative · entry 2 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,317 Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:28 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 27,835 | $118.26 | $3,291,767.10 |
DisclosureSEC source: 0001179110-18-003331 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,317 Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:52 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 45,840 | $0.00 Strike: $114.36 | $0.00 |
DisclosureSEC source: 0001179110-18-002296 · edgar.xml · derivative · entry 4 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,840 Underlying: Common Stock · 45,840 shares Expires 2028-02-14 F4 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exercisable in annual increments of 15,280 on February 15, 2019, 15,280 on February 15, 2020, and 15,280 on February 15, 2021. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:52 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 14,991 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002296 · edgar.xml · nonDerivative · entry 3 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,152 F3 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:52 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 17,319 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002296 · edgar.xml · nonDerivative · entry 2 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,161 F2 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:52 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 13,110 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002296 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,842 F1 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 16:15 UTC | GENERAL DYNAMICS CORP GD · Entity 2916 | Tax withholdingCommon Stock | 135 | $201.99 | $27,268.65 |
DisclosureSEC source: 0001209191-18-002330 · doc4.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,723 F1 · kind: Represents the withholding of shares of Common Stock under the General Dynamics Corporation equity compensation plan to satisfy tax withholding obligations in connection with the release of restricted shares. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 21:55 UTC | GENERAL DYNAMICS CORP GD · Entity 2916 | GrantCommon Stock | 107 | $198.11 | $21,197.77 |
DisclosureSEC source: 0001209191-17-066669 · doc4.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,858 F1 · kind: Reflects stock received in lieu of director fees in accordance with outside directors' compensation program. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.